Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dinutuximab · Unituxin, APN-311

Monoclonal antibody · Immune activation, directed at ganglioside GD2 · developed by United Therap

Approved FDA, Mar 2015
UTHR Developer
1 Registered trials

What is Dinutuximab?

Dinutuximab is a GD2-binding monoclonal antibody that binds the glycolipid GD2 on the surface of neuroblastoma cells and induces their lysis through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. It is studied in neuroblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Unituxin, APN-311
Drug type
Monoclonal antibody
Targets
ganglioside GD2
Mechanism
Immune activation, directed at ganglioside GD2
Pathways
antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity
Therapy area
Oncology
Developer
United Therap (UTHR)
FDA status
Approved as Unituxin (March 10, 2015), BLA125516 · FDA label
UNII
7SQY4ZUD30

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 6, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06450041 Phase 2 Neuroblastoma Recruiting UTHR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Neuroblastoma

More from United Therap

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the UTHR page.

Follow UTHR, the company behind Dinutuximab

See UTHR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

UTHR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.